A Look Ahead: Clinical Trials and PV Over the Next 5 Years
Given the severity of industry disruptions in 2020, and the surge in innovation and development that followed, the future of clinical operations seems more clouded than ever. Proventa set out to find out more about the future of Clinical Trials...
4 weeks agoA Look Ahead: Clinical Trials and PV Over the Next 5 Years
Given the severity of industry disruptions in 2020, and the surge in innovation and development that followed, the future of clinical operations seems more clouded than ever. Proventa set out to find out more about the future of Clinical Trials...
4 weeks ago
The Future of Clinical Trials and Pharmacovigilance
This year, Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Clinical Trials/Pharmacovigilance...
7 months agoThe Future of Clinical Trials and Pharmacovigilance
This year, Proventa debuted its successful online event format for the first time, providing experts from across the sector with an online forum just as useful and educational as our physical events have always been. During the recent Clinical Trials/Pharmacovigilance...
7 months ago
Antibiotic Resistance: Is Pharma Doing Enough?
Developed resistances to certain antibiotics have occurred since their creation in the 1940s. Scientists found the first case of resistance just four years after antibiotics entered mass production. Only recently, however, has the issue taken a critical turn. Resistant strains of...
1 year agoAntibiotic Resistance: Is Pharma Doing Enough?
Developed resistances to certain antibiotics have occurred since their creation in the 1940s. Scientists found the first case of resistance just four years after antibiotics entered mass production. Only recently, however, has the issue taken a critical turn. Resistant strains of...
1 year ago
AI and Pharmacovigilance ADR processing
Many of the problems that have long been inherent in Pharmacovigilance (PV) - such as historic limitations in the information that is published in case reports, analysis of electronic health records and integration - have found an answer in the...
1 year agoAI and Pharmacovigilance ADR processing
Many of the problems that have long been inherent in Pharmacovigilance (PV) - such as historic limitations in the information that is published in case reports, analysis of electronic health records and integration - have found an answer in the...
1 year ago
The Abbvie-Allergan Deal: A Matter of Distrust?
Compared to the merger announcement itself, the industry reaction to the $63 billion Abbvie buyout of Allergan, announced this June, was no big surprise. Abbvie, seeking to replace its now-ageing blockbuster drug Humira, was the only suitor for the Botox...
1 year agoThe Abbvie-Allergan Deal: A Matter of Distrust?
Compared to the merger announcement itself, the industry reaction to the $63 billion Abbvie buyout of Allergan, announced this June, was no big surprise. Abbvie, seeking to replace its now-ageing blockbuster drug Humira, was the only suitor for the Botox...
1 year ago